Julien Gotchac

Dr. Julien Gotchac

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
JGJulien Gotchac
Julien Gotchac
FPFlorian Poullenot
Florian Poullenot
DGDominique Guimber
Dominique Guimber
EEEmmanuelle Ecochard-Dugelay
Emmanuelle Ecochard-Dugelay
Stéphane M. SchneiderStéphane M. Schneider
Stéphane M. Schneider
RERaphaël ENAUD
Raphaël ENAUD
Although central venous catheter (CVC)-related thrombosis (CRT) is a severe complication of home parenteral nutrition (HPN), the amount and quality of data in the diagnosis and management of CRT remain low. We aimed to describe current practices regarding CVC management in French adult and pediatric HPN centers, with a focus on CVC obstruction and CRT. Current practices regarding CVC management in patients on HPN were collected by an online-based cross-sectional survey sent to expert physicians of French HPN centers. We compared these practices to published guidelines and searched for differences between pediatric and adult HPN centers’ practices. Finally, we examined the heterogeneity of practices in both pediatric and adult HPN centers. The survey was completed by 34 centers, including 21 pediatric and 13 adult centers. We found a considerable heterogeneity, especially in the responses of pediatric centers. On some points, the centers’ responses differed from the current guidelines. We also found significant differences between practices in adult and pediatric centers. We conclude that the management of CVC and CRT in patients on HPN is a serious and complex situation for which there is significant heterogeneity between HPN centers. These findings highlight the need for more well-designed clinical trials in this field.

14 December 2022 in Archives de Pédiatrie
Verified
Journal Article
Closed access
JLJ. Labat
J. Labat
CBC. Brocard
C. Brocard
YBY. Belaroussi
Y. Belaroussi
CBC. Bar
C. Bar
JGJulien Gotchac
Julien Gotchac
OBO. Brissaud
O. Brissaud

7 May 2025 in BMC Pediatrics
Verified
Journal Article
Open access
PDF file
JGJulien Gotchac
Julien Gotchac
ANAnouk Navion
Anouk Navion
YBYaniss Belaroussi
Yaniss Belaroussi
RKRoman Klifa
Roman Klifa
PAPascal Amedro
Pascal Amedro
OBOlivier Brissaud
Olivier Brissaud
Predicting fluid responsiveness is challenging in infants. It is however crucial to avoid unnecessary volume expansion, which can lead to fluid overload. We tested the hypothesis that the stroke volume changes induced by a calibrated abdominal compression (ΔSV-AC) could predict fluid responsiveness in infants without cardiac disease. This prospective single center study of diagnostic test accuracy was conducted in a general pediatric intensive care unit (PICU). Children under the age of two with acute circulatory failure and requiring a 10 mL.kg−1 crystalloid volume expansion over 20 min, ventilated or not ventilated, were eligible. Stroke volume was measured by transthoracic echocardiography at baseline, during a gentle calibrated abdominal compression (22 mmHg for 30 s), and after volume expansion. The area under the receiver operating characteristic curve (AUROC) of ΔSV-AC was measured to predict fluid responsiveness, defined as a 15% stroke volume increase after volume expansion. Twenty-seven cases of volume expansion were analyzed, in 21 patients. Seventeen VE cases were administrated to spontaneously breathing children. Fluid responsiveness was observed in 12 cases. The AUROC of ΔSV-AC was 0.93 (95% confidence interval (95%CI) 0.82–1). The best threshold value for ΔSV-AC was 9.5%. At this threshold value, sensitivity was 92% (95%CI 62–100), specificity was 87% (95%CI 60–98), positive and negative predictive values were 85% (95%CI 60–95) and 93% (95%CI 66–99) respectively. Echocardiographic assessment of stroke volume changes induced by a calibrated abdominal compression is a promising method to predict fluid responsiveness in infants without cardiac disease hospitalized in PICU. ClinicalTrials.gov registration number NCT05919719, June 22, 2023, retrospectively registered, https://clinicaltrials.gov/study/NCT05919719 .

11 October 2025 in European Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
JGJulien Gotchac
Julien Gotchac
EWElvina De Witte
Elvina De Witte
YBYaniss Belaroussi
Yaniss Belaroussi
JGJulie Guichoux
Julie Guichoux
TDThomas Dienst
Thomas Dienst
OBOlivier Brissaud
Olivier Brissaud
The respiratory management of neonates with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia (TH) is a challenging issue, but remai

7 July 2026 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
PAPascal Amedro
Pascal Amedro
MAMathieu Andrianoely
Mathieu Andrianoely
PGPauline Gohier
Pauline Gohier
JLJustine Leroux
Justine Leroux
NANathalie Aladjidi
Nathalie Aladjidi
JGJulien Gotchac
Julien Gotchac
Background: Barth syndrome (BTHS) is a rare X-linked mitochondrial disorder characterized by cardiomyopathy, neutropenia, and skeletal myopathy. Elamipretide is a mitochondria-targeting peptide that stabilizes cardiolipin and improves mitochondrial function. While use of this treatment in infants with BTHS has been reported in the United States, no cases have been described outside the US or in older children. Case presentation: We report the first case of a preschool-aged child with genetically confirmed BTHS and advanced heart failure, who was treated with elamipretide under a compassionate use program approved by the French Drug Administration (ANSM). At treatment initiation, this 5-year-old patient presented with severe left ventricular dysfunction (LVEF = 20%) and moderate-to-severe mitral regurgitation. He was dependent on gastrostomy feeding and had been listed for heart transplantation. Subcutaneous elamipretide (10 mg/day) was initiated alongside maximal conventional heart failure therapy. Over six months, LVEF improved to 50%, mitral regurgitation decreased to mild, Ross class improved from IV to I, and substantial gains were observed in functional capacity, nutritional status, and health-related quality of life (HRQoL). The patient returned to full-time school and remained temporarily suspended from the transplant list. Treatment was generally well tolerated. One transient, non-serious episode of abdominal pain with moderate pancreatic enzyme elevation occurred, which resolved without treatment discontinuation. Conclusions: This case suggests that elamipretide may improve cardiac function, exercise tolerance, nutrition, and HRQoL in preschool-aged pediatric BTHS patients, potentially delaying the need for transplantation. Broader pediatric evaluation is warranted. Further strategies, such as youth-tailored hybrid cardiac rehabilitation programs, could complement pharmacological therapy and further optimize outcomes in this population.

10 September 2022 in Perfectionnement en Pédiatrie
Verified
Journal Article
Closed access
JGJulien Gotchac
Julien Gotchac